
Bank Watch Barclays outperformance past sell by date
Barclays’ shares may be running ahead of reality.
Share this:

Bank Watch: Barclays outperformance past sell-by date
Barclays’ shares may be running ahead of reality. Since mid-November, stock in the UK’s No. 2 bank by assets is up 16%. That compares with London’s main bank index which has given up a rise half the size of Barclays’ to trade flat by Monday. Barclays even neared an incongruous match with its much larger U.S. rival JPMorgan, which has added 17% since 13th November. How are Barclays’ shares keeping pace with JPMorgan’s?
No nasty surprises
The answer is partly internal and partly external. Chiefly, despite reporting a £2bn full-year loss in February amid slipping revenues most causes—like losses from selling African assets—were already known to investors. Furthermore, the one-off charge linked to U.S. tax reform, responsible for another large dent, wasn’t a performance issue and followed similar costly adjustments at rivals. Investors weren’t necessarily that impressed by CEO Jes Staley’s confidence “in the capacity of this business to generate excess capital”. However the resumption of the group’s full dividend after a year-and-a half pause went a long way. Some investor relief was apparent in anticipation, whilst on-target costs pointed to improved visibility in 2018.
Attractive optics
At the same time, parlous as Barclays’ 21% tumble in quarterly trading revenue was, it still outperformed many large rivals. Growth at global lenders was after all mediocre last year as a cost reduction and efficiency boosting recovery phase drew to a close. Indeed at 2.8%, Barclays’s net interest margin is forecast to beat UK peers over the next 12 months, according to Thomson Reuters data. With the price of its shares relative to book value some 30 basis points below average, in line with a tardier recovery, a less demanding Barclays valuation has attractive optics too.
Powerful recovery while it lasts
None of this means Barclays is likely to pace the field in 2018. Whilst its UK consumer franchise is the most profitable around, international businesses will keep dragging on group returns. Hitting a 9% return on tangible equity target by 2019 would require revenue to grow by an implausible 10%. That’s before factoring in costs from Barclays’ numerous outstanding conduct matters. Still, recovery and price momentum are powerful forces with real growth in the sector still uncertain.
Thoughts on Barclays share price chart
After an arduous trek up from November lows, BARC last week arrived at the same overhead barrier that ended prior attempts last May and July. Resistance at 214p held though. A reversal at the end of February found support at the 21-day exponential moving average, but a flattening 200-day average and little clear absolute price support nearby point to another sustained failure for the time being. Buying could lose further traction if
- Implied support from 38.2% of the rise from Brexit vote lows to cycle highs collapses
- A nascent rising trend line that commenced in November gives way, opening up risks of a test of probably weak short-term support around 188p.
At this point, a break above 214p is the only way Barclays’ recovery would become credible on a technical basis.
Related tags:
Latest market news
View more newsOpen an account today
Experience award-winning platforms with fast and secure execution.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

SK Hynix IPO: Everything You Need to Know About SK Hynix
Learn everything you need to know about the SK Hynix IPO, including its Nasdaq listing, valuation, financials, ownership, competitors and investment risks.

Nasdaq 100 Outlook: Broadcom Extends Slide, Palantir Reversal Signal
Nasdaq 100 slides as AI funding fears bite, with Broadcom extending losses and Palantir flashing a potential reversal at resistance.

ASX 200 Market Wrap: Big Four Bounce, FMG Surges, CSL Lags
ASX 200 posts its best day in three months as big four banks rebound, FMG breaks higher and CSL continues to lag the market.
From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.





